News

Revolutionizing Patient Care with Harrow's New Sedation Pill

Revolutionizing Patient Care with Harrow's New Sedation Pill

Harrow's Innovative Step Towards Enhanced Patient Care

Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of advanced ophthalmic disease management solutions, has taken a significant step forward by announcing its agreement to acquire Melt Pharmaceuticals, Inc.. This clinical-stage company specializes in developing non-opioid, non-IV sedation therapies aimed at improving hospital and outpatient care.

Impact of the Acquisition

This acquisition is more than just a business move; it represents a crucial advancement in Harrow's mission to provide innovative and patient-focused ophthalmic management solutions that transcend the limitations of traditional treatment approaches. By integrating Melt's expertise and product offerings, Harrow is strategically positioning itself to revolutionize outpatient medical procedures.

MELT-300: A Game-Changer in Sedation

Melt’s flagship product, MELT-300, is a groundbreaking sublingual tablet containing 3 mg of midazolam and 50 mg of ketamine. It offers rapid and reliable sedation and pain relief without needing intravenous methods, thereby enhancing outpatient treatment experiences and addressing the urgent need to reduce opioid dependence.

Potential Benefits for Patients

According to Mark L. Baum, Chief Executive Officer of Harrow, “MELT-300 has the potential to redefine the standard of care for millions of patients by providing a convenient, non-opioid alternative for procedural sedation.” This innovation aims to make medical procedures less daunting for patients while providing effective outcomes.

Looking Forward: Regulatory Submissions and Market Entry

Harrow's commitment to expanding its product line includes plans to submit a New Drug Application (NDA) for MELT-300 to the FDA with hopes of gaining approval by 2027 for a market launch in 2028. The LOUISE Phase 3 clinical trial, conducted under a Special Protocol Assessment with the U.S. FDA, provides strong support for this application and the product's potential for regulatory approval.

Harrow's Experience in the Field

Building on over a decade of experience, Harrow has proven its effectiveness with its MKO Melt sublingual sedation used in over 500,000 cataract surgeries. This established platform positions Harrow favorably as it aims to capture a slice of the lucrative multi-billion-dollar U.S. procedural sedation market.

Future Applications and Market Impact

Upon successful FDA approval of MELT-300, Harrow plans to pivot towards this new offering while discontinuing the MKO Melt. Beyond its immediate applications in ophthalmic procedures, the formulation of MELT-300 has potential uses in various outpatient settings, including colonoscopies, MRIs, and dental procedures. This versatility is expected to significantly diversify Harrow’s perioperative product offerings and contribute to decreasing opioid dependence.

Technological Edge in Delivery

Utilizing Catalent’s Zydis oral dissolving tablet technology, MELT-300 is designed to enhance patient comfort by providing a needle-free solution. It allows for easy administration in both hospital and outpatient environments, aiming to improve patient experiences and outcomes.

Global Reach and Commercialization Plans

The innovative product is patented in North America, Europe, Asia, Australia, and the Middle East, with Harrow actively seeking global partners to facilitate its commercialization. The company is focused on ensuring wide access to this FDA-approved product once it receives regulatory clearance.

Price Action: HROW shares saw an increase of 1.84%, reaching $47.00 in premarket trading at the last check.

Frequently Asked Questions

What is Harrow's recent acquisition?

Harrow, Inc. has agreed to acquire Melt Pharmaceuticals, which focuses on non-opioid sedation therapies.

What is MELT-300?

MELT-300 is a sublingual tablet designed to provide sedation and pain relief without intravenous administration.

When does Harrow plan to seek FDA approval for MELT-300?

Harrow intends to submit a New Drug Application for MELT-300 to the FDA by 2027.

How does this product benefit outpatient procedures?

MELT-300 enhances patient comfort, reduces opioid use, and provides a non-invasive sedation method.

What markets is Harrow targeting with MELT-300?

The product has potential applications in ophthalmology, dentistry, gastroenterology, and other outpatient procedures.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 0

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 24

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 117

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 0

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

T. Rowe Price OHA Credit Fund Reports Strong Q2 Performance

Updated Category News Views 146

Financial Performance Overview T. Rowe Price OHA Select Private Credit Fund (NASDAQ: OCREDIT) recently reported its financial results for the quarter ended June 30, 2025. The fund declared total distributions amounting to $0.81 per share for this period. This reflects the growing significance of private credit as a financing solution in today's credit markets. Investment...

Continue Reading
Toll Brothers Unveils Luxurious Townhome Community in Armonk

Updated Category News Views 222

Discover the Enclave at Armonk Located in Armonk, the newly launched Enclave at Armonk invites homebuyers to experience luxury living blended with convenience. This new community by Toll Brothers represents a significant addition to the Westchester County real estate market, bringing elegant townhome designs that promise sophistication and comfort. A Closer Look at the...

Continue Reading
XAI Octagon Trust Expands Opportunities with New Preferred Shares

Updated Category News Views 108

XAI Octagon Trust Issues Convertible Preferred Shares XAI Octagon Floating Rate & Alternative Income Trust (NYSE:XFLT), a diversified closed-end management investment company, has made a significant move by announcing the issuance and sale of 400,000 shares of its 6.95% Series II 2029 Convertible Preferred Shares. This initiative enhances the Trust's capital resources and...

Continue Reading
Endeavour Mining's Recent Share Buyback Activity Overview

Updated Category News Views 208

Endeavour Mining Announces Recent Share Buyback In a significant move for shareholders, Endeavour Mining plc (LSE: EDV, TSX: EDV) has disclosed its recent buyback of ordinary shares. These transactions showcase the company's ongoing commitment to enhancing shareholder value and demonstrate a strategic approach to managing its equity. Details of the Share Buyback Endeavour...

Continue Reading
Sleep Awareness Week 2025: Importance of Quality Sleep

Updated Category News Views 459

National Sleep Foundation Announces 2025 Dates for Sleep Awareness Week Today, the National Sleep Foundation (NSF) has shared that Sleep Awareness Week in 2025 will be observed from March 9 to March 15. This annual campaign aims to highlight the critical role sleep plays in promoting health and overall well-being, encouraging the public to prioritize high-quality sleep....

Continue Reading